Pankaj Bhargava, āshibio CEO
June 20, 2024 08:30 AM EDT
Financing
Startups

Gilead test­ed an an­ti­body many times. A small biotech sal­vages it, with $40M and ‘con­vic­tion’ else­where

Kyle LaHucik

Senior Reporter

Gilead had test­ed a hu­man­ized an­ti­body called an­de­cal­ix­imab, or GS-5745, in close to 1,000 pa­tients be­fore giv­ing up on it a few years ago. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: Vi­jay Pande hands a16z biotech lead­er­ship to Vi­nee­ta Agar­wala, moves to AI role

Po­lice ar­rest per­son of in­ter­est in con­nec­tion with killing of Unit­ed­Health­care CEO

ADC sci­en­tist who paved the way for Dai­ichi’s En­her­tu dies

Trump el­e­vates dis­proven link be­tween vac­cines and autism, say­ing ‘some­thing is go­ing on’

Agios' stock drops af­ter dis­clos­ing new liv­er-re­lat­ed safe­ty warn­ing in fil­ing to FDA

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times